ALX Oncology Holdings Inc.(ALXO)Earnings, Financials & Key Ratios
ALXO•NASDAQ
$1.93
$103M mkt cap·Price updated May 6, 2026
AboutALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$142M+16.4%
- Net Income-$135M+16.1%
- EPS (Diluted)-2.58+31.0%
- ROE-88.91%-25.3%
- ROIC-71.82%-15.2%
- Debt/Equity0.15+64.8%
- Interest Coverage-82.40+24.3%
ALXO Key Insights
ALX Oncology Holdings Inc. (ALXO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 21.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ALXO Price & Volume
ALX Oncology Holdings Inc. (ALXO) stock price & volume — 10-year historical chart
Loading chart...
ALXO Growth Metrics
ALX Oncology Holdings Inc. (ALXO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM28.55%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM31.88%
Return on Capital
10 Years-91.31%
5 Years-47.16%
3 Years-64.91%
Last Year-84.85%
ALXO Recent Earnings
ALX Oncology Holdings Inc. (ALXO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q1 2026Latest
Feb 27, 2026EPS
$0.42
Est $0.38
-10.5%
Revenue
—
Q4 2025
Nov 7, 2025EPS
$0.41
Est $0.37
-10.8%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.49
Est $0.46
-6.5%
Revenue
—
Q2 2025
May 8, 2025EPS
$0.58
Est $0.47
-23.4%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 27, 2026 | $0.42vs $0.38-10.5% | — |
| Q4 2025 | Nov 7, 2025 | $0.41vs $0.37-10.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.49vs $0.46-6.5% | — |
| Q2 2025 | May 8, 2025 | $0.58vs $0.47-23.4% | — |
Based on last 12 quarters of dataView full earnings history →
ALXO Peer Comparison
ALX Oncology Holdings Inc. (ALXO) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 272.25M | 2.36 | -2.05 | -51.24% | -20.51% | -65.79% | 0.38 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 147.29M | 4.17 | -1226.47 | 10.37% | 0.1% | |||
 NKTR | 1.65B | 84.16 | -8.65 | -43.89% | -192.87% | -356.81% | 0.95 | |
 MGNX | 199.45M | 3.15 | -2.67 | 0.78% | -49.91% | -120.2% | 0.66 | |
 EXEL | 11.28B | 44.42 | 15.98 | 6.98% | 35.08% | 40.21% | 7.48% | 0.08 |
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% |
Compare ALXO vs Peers
ALX Oncology Holdings Inc. (ALXO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALXO Income Statement
ALX Oncology Holdings Inc. (ALXO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.07M | 4.8M | 1.18M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | 132.03% | -75.35% | -100% | - | - | - | - |
| Cost of Goods Sold | 1.88M | 4.36M | 1.07M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 90.95% | 90.91% | 90.95% | - | - | - | - | - |
| Gross Profit | 187K▲ 0% | 436K▲ 133.2% | 107K▼ 75.5% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | 9.05% | 9.09% | 9.05% | - | - | - | - | - |
| Gross Profit Growth % | - | 133.16% | -75.46% | -100% | - | - | - | - |
| Operating Expenses | 13.87M | 19.62M | 43.77M | 83.56M | 127.44M | 170.28M | 142.47M | 111.61M |
| OpEx % of Revenue | 671.07% | 409.07% | 3703.05% | - | - | - | - | - |
| Selling, General & Admin | 2.6M | 3.31M | 14.81M | 23.39M | 29.04M | 28.48M | 26.09M | 25.55M |
| SG&A % of Revenue | 125.83% | 69.08% | 1252.88% | - | - | - | - | - |
| Research & Development | 11.27M | 16.31M | 28.96M | 60.17M | 98.4M | 141.79M | 116.37M | 82.88M |
| R&D % of Revenue | 545.23% | 339.99% | 2450.17% | - | - | - | - | - |
| Other Operating Expenses | -2K | 0 | 0 | 0 | 0 | 0 | 0 | 1000K |
| Operating Income | -13.68M▲ 0% | -19.18M▼ 40.2% | -43.66M▼ 127.6% | -83.56M▼ 91.4% | -127.44M▼ 52.5% | -170.28M▼ 33.6% | -142.47M▲ 16.3% | -111.61M▲ 0% |
| Operating Margin % | -662.02% | -399.98% | -3693.99% | - | - | - | - | - |
| Operating Income Growth % | - | -40.19% | -127.61% | -91.36% | -52.52% | -33.62% | 16.33% | - |
| EBITDA | -13.25M | -18.75M | -43.46M | -83.5M | -127.09M | -169.44M | -141.59M | -110.84M |
| EBITDA Margin % | -641.17% | -391.03% | -3676.9% | - | - | - | - | - |
| EBITDA Growth % | - | -41.51% | -131.74% | -92.14% | -52.2% | -33.32% | 16.43% | 30.29% |
| D&A (Non-Cash Add-back) | 431K | 429K | 202K | 51K | 342K | 836K | 872K | 769K |
| EBIT | -13.69M | -19.19M | -43.66M | -83.47M | -123.18M | -159.24M | -133.12M | -106.36M |
| Net Interest Income | 0 | -21K | -811K | -12.91K | 4.04M | 9.08M | 7.64M | 3.62M |
| Interest Income | 0 | 0 | 0 | 91 | 4.28M | 10.65M | 9.37M | 5.27M |
| Interest Expense | 0 | 21K | 811K | 13K | 238K | 1.56M | 1.73M | 1.65M |
| Other Income/Expense | -2K | -26K | -1.84M | 71K | 4.02M | 9.47M | 7.62M | 3.6M |
| Pretax Income | -13.69M▲ 0% | -19.21M▼ 40.4% | -45.5M▼ 136.9% | -83.48M▼ 83.5% | -123.42M▼ 47.8% | -160.81M▼ 30.3% | -134.85M▲ 16.1% | -108.01M▲ 0% |
| Pretax Margin % | -662.12% | -400.52% | -3849.32% | - | - | - | - | - |
| Income Tax | 45K | 34K | 241K | -21K | 64K | 0 | 0 | 0 |
| Effective Tax Rate % | -0.33% | -0.18% | -0.53% | 0.03% | -0.05% | 0% | 0% | 0% |
| Net Income | -13.73M▲ 0% | -19.24M▼ 40.1% | -45.74M▼ 137.7% | -83.46M▼ 82.5% | -123.48M▼ 47.9% | -160.81M▼ 30.2% | -134.85M▲ 16.1% | -108.01M▲ 0% |
| Net Margin % | -664.3% | -401.23% | -3869.71% | - | - | - | - | - |
| Net Income Growth % | - | -40.14% | -137.7% | -82.47% | -47.95% | -30.23% | 16.14% | 28.55% |
| Net Income (Continuing) | -13.73M | -19.24M | -45.74M | -83.46M | -123.48M | -160.81M | -134.85M | -108.01M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.63▲ 0% | -0.88▼ 39.7% | -1.28▼ 45.5% | -2.07▼ 61.7% | -3.03▼ 46.4% | -3.74▼ 23.4% | -2.58▲ 31.0% | -2.02▲ 0% |
| EPS Growth % | - | -39.68% | -45.45% | -61.72% | -46.38% | -23.43% | 31.02% | 31.88% |
| EPS (Basic) | -0.63 | -0.88 | -1.28 | -2.07 | -3.03 | -3.74 | -2.58 | - |
| Diluted Shares Outstanding | 21.95M | 21.95M | 39.84M | 40.31M | 40.7M | 42.99M | 52.17M | 53.58M |
| Basic Shares Outstanding | 21.95M | 21.95M | 39.84M | 40.31M | 40.7M | 42.99M | 52.17M | 53.58M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ALXO Balance Sheet
ALX Oncology Holdings Inc. (ALXO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.21M | 9.81M | 435.99M | 367.02M | 270.97M | 188.66M | 134.35M | 66.52M |
| Cash & Short-Term Investments | 8.26M | 9.02M | 434.22M | 363.67M | 266.21M | 182.74M | 127.76M | 60.63M |
| Cash Only | 8.26M | 9.02M | 434.22M | 363.67M | 48.82M | 22.41M | 17.57M | 23.44M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 217.38M | 160.33M | 110.19M | 37.18M |
| Accounts Receivable | 932K | 536K | 0 | 0 | 0 | 0 | 892K | 0 |
| Days Sales Outstanding | 164.58 | 40.79 | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 4.76M | 5.92M | 5.7M | 5.89M |
| Total Non-Current Assets | 956K | 867K | 62K | 13.16M | 35.52M | 53.89M | 13.42M | 16.21M |
| Property, Plant & Equipment | 956K | 860K | 52K | 3.47M | 9.81M | 10.84M | 9.63M | 1.35M |
| Fixed Asset Turnover | 2.16x | 5.58x | 22.73x | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 16.7M | 35.41M | 3.52M | 22.75M |
| Other Non-Current Assets | 0 | 7K | 10K | 9.69M | 9.01M | 7.64M | 267K | 13.87M |
| Total Assets | 11.16M▲ 0% | 10.68M▼ 4.4% | 436.05M▲ 3984.4% | 380.18M▼ 12.8% | 306.49M▼ 19.4% | 242.55M▼ 20.9% | 147.78M▼ 39.1% | 82.72M▲ 0% |
| Asset Turnover | 0.19x | 0.45x | 0.00x | - | - | - | - | 0.00x |
| Asset Growth % | - | -4.37% | 3984.43% | -12.81% | -19.38% | -20.86% | -39.08% | -193.26% |
| Total Current Liabilities | 1.87M | 4.98M | 6.2M | 15.29M | 28.32M | 36M | 18.5M | 27.72M |
| Accounts Payable | 697K | 3.75M | 4K | 3.76M | 8.07M | 8.59M | 4.5M | 6.58M |
| Days Payables Outstanding | 135.32 | 313.77 | 1.36 | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 435K | 4.35M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 369K | 1.06M | 2.13M | 3.53M | 4.72M | 6.7M | 5.97M | 16.79M |
| Current Ratio | 5.45x | 1.97x | 70.28x | 24.00x | 9.57x | 5.24x | 7.26x | 7.26x |
| Quick Ratio | 5.45x | 1.97x | 70.28x | 24.00x | 9.57x | 5.24x | 7.26x | 7.26x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 136K | 5.97M | 5K | 1.84M | 14.7M | 16.84M | 15.66M | 10.2M |
| Long-Term Debt | 0 | 5.42M | 0 | 0 | 9.39M | 9.64M | 9.47M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 5.98M | 5.16M | 4.13M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 412K | 5K | 1.84M | 5.31M | 1.22M | 1.03M | 22.95M |
| Total Liabilities | 2.01M | 10.95M | 6.21M | 17.13M | 43.02M | 52.84M | 34.16M | 37.92M |
| Total Debt | 0 | 5.42M | 0 | 742K | 10.43M | 17.2M | 16.98M | 4.35M |
| Net Debt | -8.26M | -3.6M | -434.22M | -362.93M | -38.39M | -5.21M | -589K | -19.09M |
| Debt / Equity | - | - | - | 0.00x | 0.04x | 0.09x | 0.15x | 0.15x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.04x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.17x |
| Interest Coverage | - | -913.48x | -53.84x | -6427.31x | -535.45x | -108.80x | -82.40x | -64.62x |
| Total Equity | 9.15M▲ 0% | -276K▼ 103.0% | 429.85M▲ 155840.9% | 363.05M▼ 15.5% | 263.46M▼ 27.4% | 189.71M▼ 28.0% | 113.62M▼ 40.1% | 44.8M▲ 0% |
| Equity Growth % | - | -103.01% | 155840.94% | -15.54% | -27.43% | -27.99% | -40.11% | -213.16% |
| Book Value per Share | 0.42 | -0.01 | 10.79 | 9.01 | 6.47 | 4.41 | 2.18 | 0.84 |
| Total Shareholders' Equity | 9.15M | -276K | 429.85M | 363.05M | 263.46M | 189.71M | 113.62M | 44.8M |
| Common Stock | 3K | 3K | 40K | 41K | 41K | 50K | 53K | 54K |
| Retained Earnings | -53.54M | -72.78M | -118.52M | -201.99M | -325.47M | -486.27M | -621.12M | -699.97M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.02M | 0 | 0 | 0 | -845K | 256K | 275K | 43K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ALXO Cash Flow Statement
ALX Oncology Holdings Inc. (ALXO) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -13.19M | -14.25M | -38.29M | -68.1M | -89.22M | -130.36M | -121.91M | -121.91M |
| Operating CF Margin % | -638.12% | -297.1% | -3239.34% | - | - | - | - | - |
| Operating CF Growth % | - | -8.03% | -168.71% | -77.86% | -31.02% | -46.11% | 6.48% | 98.74% |
| Net Income | -13.73M | -19.24M | -45.74M | -83.46M | -123.48M | -160.81M | -134.85M | -108.01M |
| Depreciation & Amortization | 431K | 429K | 202K | 51K | 342K | 836K | 872K | 769K |
| Stock-Based Compensation | 269K | 297K | 5.44M | 13.91M | 23.84M | 26.27M | 27.09M | 15.73M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.33M | 11K | 1.57M | 5.42M | 228K | -4.96M | -2.6M | 3.46M |
| Working Capital Changes | -159K | 4.26M | 247K | -4.03M | 9.85M | 8.3M | -12.43M | -9.16M |
| Change in Receivables | -932K | 396K | 536K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -269K | 2.98M | -3.74M | 3.29M | 4.51M | 458K | -4.02M | -1.69M |
| Cash from Investing | -653K | -353K | 610K | -4.92M | -235.42M | 44.66M | 86.26M | 104.54M |
| Capital Expenditures | -653K | -353K | -31K | -4.92M | -1.43M | -1.27M | -447K | -223K |
| CapEx % of Revenue | 31.59% | 7.36% | 2.62% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 233.99K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 641K | 0 | -233.99K | 0 | 0 | 0 |
| Cash from Financing | 1K | 15.36M | 462.88M | 2.47M | 9.86M | 59.29M | 30.82M | 12K |
| Debt Issued (Net) | 0 | 5.92M | 0 | -281K | 9.61M | -388K | -827K | -780K |
| Equity Issued (Net) | -6K | 1000K | 1000K | 1000K | 903K | 1000K | 1000K | -613K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 7K | 10K | -10.05M | 0 | -655K | 792K | 0 | 29.71M |
| Net Change in Cash | -13.84M▲ 0% | 755K▲ 105.5% | 425.2M▲ 56218.1% | -70.55M▼ 116.6% | -314.78M▼ 346.2% | -26.42M▲ 91.6% | -4.84M▲ 81.7% | 7.34M▲ 0% |
| Free Cash Flow | -13.84M▲ 0% | -14.6M▼ 5.5% | -38.32M▼ 162.4% | -73.02M▼ 90.6% | -90.65M▼ 24.1% | -131.64M▼ 45.2% | -122.36M▲ 7.0% | -97.43M▲ 0% |
| FCF Margin % | -669.71% | -304.46% | -3241.96% | - | - | - | - | - |
| FCF Growth % | - | -5.48% | -162.43% | -90.56% | -24.14% | -45.22% | 7.05% | 25.1% |
| FCF per Share | -0.63 | -0.67 | -0.96 | -1.81 | -2.23 | -3.06 | -2.35 | -2.35 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.74x | 0.84x | 0.82x | 0.72x | 0.81x | 0.90x | 0.90x |
| Interest Paid | 0 | 0 | 427K | 11K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 47K | 274K | 0 | 0 | 0 | 0 |
ALXO Key Ratios
ALX Oncology Holdings Inc. (ALXO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -433.45% | -21.3% | -21.05% | -39.42% | -70.97% | -88.91% | -241.09% |
| Return on Invested Capital (ROIC) | - | - | -50537.3% | -84.88% | -62.36% | -71.82% | -71.82% |
| Gross Margin | 9.09% | 9.05% | - | - | - | - | - |
| Net Margin | -401.23% | -3869.71% | - | - | - | - | - |
| Debt / Equity | - | - | 0.00x | 0.04x | 0.09x | 0.15x | 0.15x |
| Interest Coverage | -913.48x | -53.84x | -6427.31x | -535.45x | -108.80x | -82.40x | -64.62x |
| FCF Conversion | 0.74x | 0.84x | 0.82x | 0.72x | 0.81x | 0.90x | 0.90x |
| Revenue Growth | 132.03% | -75.35% | -100% | - | - | - | - |
ALXO Frequently Asked Questions
ALX Oncology Holdings Inc. (ALXO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ALX Oncology Holdings Inc. (ALXO) grew revenue by 0.0% over the past year. Growth has been modest.
ALX Oncology Holdings Inc. (ALXO) reported a net loss of $108.0M for fiscal year 2024.
Dividend & Returns
ALX Oncology Holdings Inc. (ALXO) has a return on equity (ROE) of -88.9%. Negative ROE indicates the company is unprofitable.
ALX Oncology Holdings Inc. (ALXO) had negative free cash flow of $97.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More ALXO
ALX Oncology Holdings Inc. (ALXO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates